



## Andrew J. Storaska\*, Ph.D. Patent Agent/Scientific Advisor

Andrew J. Storaska is experienced in a wide variety of patent law matters, including patent prosecution in the chemical, pharmaceutical, and biotechnology arts. In his current role, he handles various aspects of patent prosecution, conducts prior art searches, and performs patent landscape analysis.

During his postdoctoral research at the Cornell Medical College (New York, NY) and New York University School of Medicine (New York, NY), Dr. Storaska focused on neuroscience, investigating the molecular connections between oncogenic signaling pathways and stem cell transcriptional networks in brain tumor stem cells. Part of this work included the evaluation of FDA-approved small molecule drugs for anti-glioma effects on the stem cell phenotypes of brain tumor stem cells. Dr. Storaska also gained experience working on a human stem cell-derived cerebral organoid model of the human brain for use in cancer research.

Over the course of his doctoral work, Dr. Storaska managed several small molecule screening projects focused on identifying and developing inhibitors of protein-protein interactions. He collaborated with medicinal chemists on chemical optimization steps using a broad range of biochemical and biophysical approaches to characterize protein-small molecule interactions.

The author of many published articles, Dr. Storaska also served as a research assistant in biochemistry and biophysics at the University of Maryland (College Park), and as a chemical toxicology intern at Leadscope, Inc. and the U.S. Food and Drug Administration.

Dr. Storaska is a registered patent agent with the USPTO.

\*Not admitted to the DC Bar

### Areas of Concentration

Litigation

Patent Prosecution

### Publications & Presentations

Co-author, "Modeling patient-derived glioblastoma with cerebral organoids." Cell reports 26, no. 12 (2019): 3203-3211.

Co-author, "A Core Regulatory Circuit in Glioblastoma Stem Cells Links MAPK Activation to a Transcriptional Program of Neural Stem Cell Identity." Scientific Reports 7, (2017) Article number:



607 14th Street, N.W. Suite  
800 Washington, DC 20005  
P 202.783.6040  
F 202.783.6031

### Education

Ph.D., Pharmacology, University of Michigan, Ann Arbor - 2014

B.S., Cell Biology & Molecular Genetics, University of Maryland, College Park - 2008

### Bar Admissions

U.S. Patent and Trademark Office

43605.

Co-author, "Selectivity and anti-Parkinson's potential of thiazolidinone RGS4 inhibitors." *ACS Chem Neuroscience* 6, (2015) 911-919.

Co-author, "Redox Modification of Nuclear Actin by MICAL-2 Regulates SRF Signaling." *Cell* 15, (2014) 563-76.

Storaska, A. J., et al. "Conformational Dynamics of a Regulator of G-Protein Signaling Protein Reveals a Mechanism of Allosteric Inhibition by a Small Molecule." *ACS Chemical Biology* 12, (2013) 2778-84. (Co-first author).

Storaska, A. J., and Neubig, R. R. "NMR methods for detection of small molecule binding to RGS4." *Methods in Enzymology* 522, (2013) 133-152.

Storaska, A. J., et al. "Reversible inhibitors of regulators of G-protein signaling identified in a high-throughput cell-based calcium signaling assay." *Cellular Signaling* 25, (2013) 2848-2855.

Co-author, "Perturbing the ubiquitin pathway reveals how mitosis is hijacked to denucleate and regulate cell proliferation and differentiation in vivo." *PloS One* 5, (2010) e13331.

Co-author, "Structure of the s5a:k48-linked diubiquitin complex and its interactions with rpn13." *Molecular Cell* 35, (2009) 280-290.